Due in part to the COVID-19 pandemic, radiation oncology firm Varian Medical Systems posted mixed financial results in its second quarter of fiscal 2020.
For the quarter (end-March 31), revenue increased 2% to $794.5 million, compared with $779.4 million in the second quarter of fiscal 2019. However, net earnings decreased to $43.1 million, compared with $88.4 million in 2019, Varian said.
Sales in the company's oncology systems segment rose 2%, from $746.8 million in 2019 to $760.5 million for this period. But Varian's proton solutions segment took a hit, with revenues totaling $22.3 million, down 32% from 2019's $32.6 million.
The company has withdrawn its March 9 guidance for 2020 due to the COVID-19 pandemic.
"The uncertainty around the severity and duration of COVID-19 has impacted the company's ability to reliably estimate the financial impact of the pandemic for the balance of the fiscal year," it said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
